Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pabst

Showing results (291-300 of 332) with videos related to

Pageof 34
Sort By:
Intensive Care Medicine|May 4, 2026
Temporal trends and prognostic factors in critically ill adult patients with acute leukemia: an individual participant data meta-analysisDara Chean, Thibault Dupont, Joseph L Nates, et al.
Leukemia|July 1, 2026
Feasibility and safety of rapid glofitamab ramp-upCeline H Liem, Rebecca Wurm-Kuczera, David Böckle, et al.
Frontiers in Oncology|October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysisJesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Blood|November 3, 2007
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA resultsLionel Adès, Miguel A Sanz, Sylvie Chevret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative GroupStefan Gröschel, Richard F Schlenk, Jan Engelmann, et al.
Blood|October 11, 2012
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)Gert J Ossenkoppele, Georg Stussi, Johan Maertens, et al.
Blood Advances|February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetAdriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Hemasphere|June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studiesCoen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Leukemia|September 3, 2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trialTim R Mocking, Lukas H Haaksma, Tom Reuvekamp, et al.
Leukemia|December 14, 2018
CD34<sup>+</sup>CD38<sup>-</sup> leukemic stem cell frequency to predict outcome in acute myeloid leukemiaWendelien Zeijlemaker, Tim Grob, Rosa Meijer, et al.
Pageof 34

Showing results (291-300 of 332) with videos related to

Sort By:
Pageof 34
Intensive Care Medicine|May 4, 2026
Temporal trends and prognostic factors in critically ill adult patients with acute leukemia: an individual participant data meta-analysisDara Chean, Thibault Dupont, Joseph L Nates, et al.
Leukemia|July 1, 2026
Feasibility and safety of rapid glofitamab ramp-upCeline H Liem, Rebecca Wurm-Kuczera, David Böckle, et al.
Frontiers in Oncology|October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysisJesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Blood|November 3, 2007
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA resultsLionel Adès, Miguel A Sanz, Sylvie Chevret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative GroupStefan Gröschel, Richard F Schlenk, Jan Engelmann, et al.
Blood|October 11, 2012
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)Gert J Ossenkoppele, Georg Stussi, Johan Maertens, et al.
Blood Advances|February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetAdriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Hemasphere|June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studiesCoen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Leukemia|September 3, 2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trialTim R Mocking, Lukas H Haaksma, Tom Reuvekamp, et al.
Leukemia|December 14, 2018
CD34<sup>+</sup>CD38<sup>-</sup> leukemic stem cell frequency to predict outcome in acute myeloid leukemiaWendelien Zeijlemaker, Tim Grob, Rosa Meijer, et al.
Pageof 34